Prevalence by HCV genotype, which can affect the efficacy of hepatitis C treatment, also varies among different geographic regions. Of the 7 different genotypes, type 1 is the most common and ...

In the United States, approximately 75% of chronic hepatitis C infections are caused by hepatitis C genotype 1, 15 to 20% by genotype 2 or 3, and less than 5% by genotypes 4, 5, or 6.

Therefore, the development and approval of effective protease inhibitors, telaprevir and boceprevir, was hailed as a new era of therapy for patients with hepatitis C genotype 1 infection. [ 2 , 3 ] ...

People with genotype 5 and 6 hepatitis C may also receive Harvoni to treat the infection. In all these cases, treatment time, dosage, and side effects remain the same as for genotype 1.

If you’ve recently received a hepatitis C diagnosis, here are a few questions to ask your doctor during your next visit. ... Each hepatitis C genotype is treated with a different type of drug.

About 10 percent of people with hepatitis C have a genotype 3 infection. This genotype is more likely to lead to cirrhosis and liver cancer than other genotypes. It also doesn’t respond as well ...

In draft guidance published today healthcare guidance body NICE has recommended simeprevir (Olysio, Janssen) as a treatment option for some people with chronic hepatitis C The draft guidance ...

Data from 3 phase 3 trials show near-100% efficacy of sofosbuvir-ledipasvir in patients with genotype 1 hepatitis C in as little as 8 weeks, without ribavirin and regardless of prior treatment.

HealthDay News — Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 ...